20959 ⎘
Medicinal preparations containing peptides; Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Cytokines; Lymphokines; Interferons Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
THERAPEUTIC PEPTIDES AND METHODS FOR TREATING AUTOIMMUNE RELATED DISEASE
#2MODULATORS OF RAR RELATED ORPHAN RECEPTORS (RORs)
#3BIOENGINEERING TERITIARY LYMPHOID STRUCTURES USING CHITOSAN-BASED HYDROGELS
#4POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY
#5IMPLANTABLE SCAFFOLDS AND METHODS OF USE
#6TNF-ALPHA VARIANT FUSION MOLECULES
#7NOVEL COMPOSITION COMPRISING ANTIBODIES
#8TARGETING moDC TO ENHANCE VACCINE EFFICACY ON MUCOSAL SURFACE
#9TNF ALPHA AND INTERLEUKIN-2 COMBINATION THERAPY FOR NON-MELANOMA SKIN CANCER
#10IMMUNOMODULATORY FUSION PROTEIN-METAL HYDROXIDE COMPLEXES AND METHODS THEREOF
#11MEDICAL PATCH FOR CONTROLLED DELIVERY OF WOUND HEALING FACTORS AND THERAPIES
#12METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND AUTOIMMUNE CONDITIONS WITH ECM-AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS
#13COMBINATION OF IL-12 AND OX40L FOR CANCER IMMUNOTHERAPY
#14ONCOLYTIC VIRUS THERAPY
#15METHODS OF PREPARATION OF SECRETOMES, AND USES THEREOF
#16METHODS FOR EVALUATION OF EXTRACELLULAR VESICLES
#17Compositions and Methods for Activating Natural Killer Cells
#18METHOD OF ENHANCING ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC)
#19COMPOSITION FOR REDUCING SIZE OR VOLUME OF TARGET TISSUE OR KIT INCLUDING SAME
#20Neutrophil-Activating Therapy for the Treatment of Cancer
#21AGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR 2 ANTIBODIES
#22PRODUCTION OF ENHANCED STEM CELL-BASED EXOSOMES AND USES IN SCAR TISSUE PREVENTION AND TREATMENT
#23RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES
#24TRAILshort ANTIBODY AND METHODS OF USE
#25THERAPEUTIC COMPOSITION AND METHOD COMBINING MULTIPLEX IMMUNOTHERAPY WITH CANCER VACCINE FOR THE TREATMENT OF CANCER
#26Modified Cell Expansion and Uses Thereof
#27POTENTIATION OF DURABLE ANTITUMOR IMMUNITY BY MULTIFACTORIAL IMMUNE MODULATION
#28THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN
#29ALUMINUM NANOCRYSTALLINE COMPOSITE IMMUNE DRUG AND PREPARATION METHOD THEREFOR AND USE THEREOF
#30TNF-ALPHA VARIANT FUSION MOLECULES
#31MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES
#32PRODUCTION OF ENHANCED STEM CELL-BASED EXOSOMES AND USES IN SCAR TISSUE PREVENTION AND TREATMENT
#33MODULATORS OF RAR-RELATED ORPHAN RECEPTORS (RORs)
#34TNFSF-L Fusion Proteins and Uses Thereof
#35KEXIN-DERIVED VACCINES TO PREVENT OR TREAT FUNGAL INFECTIONS
#36TREATMENT OF SYSTEMIC INFLAMMATORY RESPONSES
#37MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF BIOLOGICS AND PROTEINS ASSOCIATED WITH HUMAN DISEASE
#38BIOACTIVE PEPTIDES AND METHODS OF USE THEREOF
#39METHODS AND COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SEVERE INFLUENZA
#40OXAZAPHOSPHORINE ANTIBODY DRUG CONJUGATES AND METHODS OF USE
#41COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING LIVER FIBROSIS
#42MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS
#43An oncolytic virus vector coding for interleukin-7 (IL-7) polypeptide
#44USE OF NOX INHIBITORS FOR TREATMENT OF CANCER
#45CYTOSKELETAL TENSION REGULATORS AND FAS LIGAND-COMBINATION COMPOSITIONS AND METHODS OF TREATMENT USING THE SAME
#46METHODS OF USING SPLICING MODULATORS
#47MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
#48TREATMENT OF CANCER USING A HLA-A2/MAGE-A4 X CD3 BISPECIFIC ANTIBODY AND A 4-1BB (CD137) AGONIST
#49NOVEL COMBINATIONS FOR ANTIGEN BASED THERAPY
#50COMBINATION THERAPIES WITH SIRP ALPHA-BASED CHIMERIC PROTEINS
#51METHODS FOR PREVENTING AND TREATING CHRONIC PAIN
#52TREATMENT OF CANCER USING A HLA-A2/WT1 X CD3 BISPECIFIC ANTIBODY AND A 4-1BB (CD137) AGONIST
#53METHODS FOR INDUCING AN IMMUNE RESPONSE BY ADMINISTERING ACTIVATED MESENCHYMAL STEM CELLS
#54METHODS OF TREATING CANCERS HAVING A DEREGULATED NRF2/KEAP1 PATHWAY
#55COMPOSITIONS AND METHODS FOR PROMOTING THE MINERALIZATION OF BIOLOGICAL TISSUE
#56TNFR2 agonists with improved stability
#57METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS VECTOR FOR USE WITH MULTIPLE VACCINATIONS
#58COMPOSITIONS AND METHODS FOR INHIBITING THE BIOLOGICAL ACTIVITY OF SOLUBLE BIOMOLECULES
#59METHODS OF DIAGNOSING AND PREDICTING RENAL DECLINE
#60MUC16 PROMOTER CONTAINING VIRUS
#61TIL ENHANCEMENT VIA EX VIVO STIMULATION WITH CD40 AGONISTS
#62MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS
#63POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY
#64Multipotential Expanded Mesenchymal Precursor Cell Progeny (MEMP) and Uses Thereof
#65COMPOSITIONS TARGETING TUMOR ASSOCIATED MACROPHAGES AND METHODS USING SAME
#66THERAPEUTIC TARGETING OF NON-CELLULAR STRUCTURES
#67PERSONALIZED FUSION CELL VACCINES
#68METHODS OF TREATING CANCER USING TIGIT-AND LIGHT-BASED CHIMERIC PROTEINS
#69SYNERGISTIC INDUCTION OF IMMUNITY AGAINST RNA VIRUSES
#70TREATMENT OF GULF WAR ILLNESS
#71METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS VECTOR FOR USE WITH MULTIPLE VACCINATIONS
#72METHODS FOR DE-CLOAKING CANCER FROM THE IMMUNE SYSTEM THROUGH DOWNREGULATION OF CANCER-PRODUCED PREGNANCY SPECIFIC GLYCOPROTEIN
#73RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES
#74HLA-A24 AGONIST EPITOPES OF MUC1-C ONCOPROTEIN AND COMPOSITIONS AND METHODS OF USE
#75ALGINATE-COATED MESENCHYMAL STROMAL AND PROGENITOR CELLS AND METHODS FOR USING THE SAME
#76NANOPARTICLES AND METHODS OF MANUFACTURE THEREOF
#77IMMUNOMODULATORY FUSION PROTEIN-METAL HYDROXIDE COMPLEXES AND METHODS THEREOF
#78CERTAIN ARYL PLADIENOLIDE COMPOUNDS AND METHODS OF USE
#79NANOPARTICLES INCLUDING A GLATIRAMOID USEFUL IN POLYNUCLEOTIDE DELIVERY
#80Compositions and Methods Related to Multimodal Therapeutic Cell Systems for Cancer Indications
#81COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF
#82Method of treating cancer using disulfide-linked trimeric OX40L
#83NANOPARTICLE COMPLEX WITH DEFINED SIZES
#84AUGMENTING ANTIGEN-NEGATIVE CELL DEATH IN ANTIGEN-TARGETED IMMUNOTHERAPIES
#85NK CELLS AND USES THEREOF FOR TREATMENT OF MICROBIAL INFECTIONS
#86KEXIN-DERIVED VACCINES TO PREVENT OR TREAT FUNGAL INFECTIONS
#87Antibody compositions
#88RNA FOR TREATMENT OR PROPHYLAXIS OF A LIVER DISEASE
#89Targeting gamma-delta T Cells in Obesity and Cachexia
#90POLYMERIC NANOPARTICLES PROVIDING NUCLEIC ACIDS ENCODING TNF-a
#91METHODS OF TREATING NEUROLOGICAL DISEASES
#92METHOD FOR TREATING THERAPY-RESISTANT MUC4+ CANCER
#93COMBINED USE OF CTB006 AND PONATINIB
#94DRUG DELIVERY SYSTEMS COMPRISING A NEUROTROPHIC AGENT, AN APOPTOSIS SIGNALING FRAGMENT INHIBITOR (FAS) OR FAS LIGAND (FASL) INHIBITOR, A TUMOR NECROSIS FACTOR-ALPHA (TNF-ALPHA) OR TNF RECEPTOR INHIBITOR, A MITOCHONDRIAL PEPTIDE, AN OLIGONUCLEOTIDE, A CHEMOKINE INHIBITOR, OR A CYSTEINE-ASPARTIC PROTEASE INHIBITOR
#95Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
#96MEDICAMENT COMPRISING A COMBINATION OF AMNIOTIC MEMBRANE AND UMBILICAL CORD BLOOD SERUM FOR WOUND HEALING
#97MESENCHYMAL STEM CELL EXPRESSING TRAIL AND CD, AND USE THEREOF
#98TNF MUTEINS AND USES THEREOF
#99USE OF GHOST NANOVESICLES AS THERAPEUTICS
#100Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
#101THERAPEUTIC NANOPARTICLES FOR THE TREATMENT OF NEUROBLASTOMA AND OTHER CANCERS
#102METHODS TO INCREASE THE SENSITIVITY AND REVERSING THE RESISTANCE TO DRUGS
#103REGENERATIVE BIOACTIVE SUSPENSION DERIVED FROM FRESHLY DISAGGREGATED TISSUE AND METHODS OF USE IN CLINICAL THERAPIES
#104TREATMENT OF CANCERS WITH GM-CSF ANTAGONISTS
#105CHIMERIC PROTEINS IN AUTOIMMUNITY
#106NOVEL COMPOSITION COMPRISING ANTIBODIES
#107METHOD FOR THE MANUFACTURE OF A DOSAGE FORM WITH MUCOADHESIVE PROPERTIES FOR BUCCAL ADMINISTRATION OF BIOLOGICS
#108Methods and compounds for the treatment or prevention of severe influenza
#109Methods and compositions for liquidation of tumors
#110METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING DAMAGE TO SKIN
#111Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
#112Therapeutic composition and method combining multiplex immunotherapy with cancer vaccine for the treatment of cancer
#113CELL CULTURE FOR TREATING DISEASE IN THE LOWER LIMBS
#114COMBINATION THERAPY WITH CD13-TARGETED CHIMERIC PROTEINS OR CHIMERIC PROTEIN COMPLEXES
#115TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS
#116TARGETING LUNG-RESIDENT TNFR2+ cDC2 (R2D2) SUBPOPULATION TO TREAT ASTHMA
#117COMPOSITIONS COMPRISING A TWEAK LIGAND AND METHODS OF USING SAME
#118Monocyte compositions and methods for the treatment of infectious disease
#119Methods for Modulating T Cell Activation
#120LYMPHOTOXIN ALPHA FOR USE IN THERAPY OF MYELOID LEUKEMIA
#121METHODS OF ANTI-TUMOR THERAPY
#122DYNAMIC COVALENTLY LINKED HYDROGELS AS STABILIZATION NETWORK PLATFORMS
#123BAFF THERAPY TO PROMOTE ANTI-TUMOR IMMUNITY
#124TRAILshort antibody and methods of use
#125METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY AND AUTOIMMUNE CONDITIONS WITH ECM-AFFINITY PEPTIDES LINKED TO ANTI-INFLAMMATORY AGENTS
#126Agonistic anti-tumor necrosis factor receptor 2 antibodies
#127TUMOR NECROSIS FACTOR SUPERFAMILY AND TNF-LIKE LIGAND MUTEINS AND METHODS OF PREPARING AND USING THE SAME
#128ANTIBODY-TUMOR NECROSIS FACTOR alpha FUSION PROTEIN AND ITS PREPARATION AND APPLICATIONS
#129Personalized Immunotherapies for Reduction of Brain Inflammation and Suicide Prevention
#130Therapeutic Cell Systems and Methods for Treating Cancer and Infectious Diseases
#131Compositions and Methods Related to Multimodal Therapeutic Cell Systems for Autoimmune Indications
#132Nanopatterned medical device with enhanced cellular interaction
#133TRANSDERMAL DELIVERY OF HIGH VISCOSITY BIOACTIVE AGENTS
#134Combined treatment of primary central nervous system lymphoma
#135ANTI-CANCER MONOTHERAPY USING SA-4-1BBL
#136TUMOR TREATMENT USING CYTOKINES AND CANCER DRUGS
#137NOVEL COMBINATIONS FOR ANTIGEN BASED THERAPY
#138Bioactive peptides and methods of use thereof
#139MODULATORS OF RAR-RELATED ORPHAN RECEPTORS (RORs)
#140METHODS OF TREATING AN AUTOIMMUNE DISEASE
#141DRUG CONJUGATE PREPARED USING ALDEHYDE GROUP AT END OF HYALURONIC ACID
#142CELL-FREE COMPOSITIONS AND METHODS FOR RESTORATION OR ENHANCEMENT OF TISSUE FUNCTION
#143COMBINATION THERAPIES COMPRISING SIRP ALPHA-BASED CHIMERIC PROTEINS
#144Methods and compositions for treating pain
#145IL2 AND TNF MUTANT IMMUNOCONJUGATES
#146THERAPEUTIC COMPOSITIONS AND RELATED METHODS
#147METHOD OF ENHANCING ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (ADCC)
#148METHODS OF TREATING CANCERS HAVING A DEREGULATED NRF2/KEAP1 PATHWAY
#149Multipotential Expanded Mesenchymal Precursor Cell Progeny (MEMP) and Uses Thereof
#150TARGETING moDC TO ENHANCE VACCINE EFFICACY ON MUCOSAL SURFACE
#151Nano-satellite complexes
#152Compositions and methods for inhibiting the biological activity of soluble biomolecules
#153Methods of using splicing modulators
#154METHODS FOR TREATMENT OF MICROBIAL DISORDERS
#155TISSUE HEALING AGENT
#156THERAPEUTIC PEPTIDES AND METHODS FOR TREATING AUTOIMMUNE RELATED DISEASE
#157IL-15 Variants and Uses Thereof
#158ONCOLYTIC VACCINIA VIRUS CANCER THERAPY
#159MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF BIOLOGICS AND PROTEINS ASSOCIATED WITH HUMAN DISEASE
#160NOVEL THERAPY TO ACHIEVE GLYCEMIC CONTROL
#161METHODS FOR GENERATING MACROPHAGES WITH ENHANCED CANCER PHAGOCYTOSIS
#162HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use
#163SINGLE-CHAIN CD137-RECEPTOR AGONIST PROTEINS
#164Therapeutic targeting of non-cellular structures
#165Methods for inducing an immune response by administering activated mesenchymal stem cells
#166Methods of immunotherapy
#167BIOENGINEERING TERTIARY LYMPHOID STRUCTURES USING CHITOSAN-BASED HYDROGELS
#168Methods of administering mesenchymal stem cells activated by cytokines for enhancing immunosuppression
#169Treatment of systemic inflammatory responses
#170LIGHT INHIBITORS FOR ASTHMA, LUNG AND AIRWAY INFLAMMATION, RESPIRATORY, INTERSTITIAL, PULMONARY AND FIBROTIC DISEASE TREATMENT
#171Certain aryl pladienolide compounds and methods of use
#172Use of NOX inhibitors for treatment of cancer
#173SENSITIZING CANCER TO DEATH RECEPTOR AGONISTS WITH KINASE INHIBITORS
#174KEXIN-DERIVED VACCINES TO PREVENT OR TREAT FUNGAL INFECTIONS
#175RANKL-specific agent for treating metastatic disease
#176MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE
#177Stabilized Composition
#178Antibody compositions
#179IN VIVO PRODUCTION OF PROTEINS
#180Modified cell expansion and uses thereof
#181Nucleic acids encoding p75NTR neurotrophin binding proteins
#182IN SITU METHODS OF INDUCING OF IMMUNE RESPONSE
#183COMPOSITIONS FOR TREATING INFECTIVE ARTERIAL DISEASES AND RELATED CONDITIONS
#184Composite microneedle array including nanostructures thereon
#185SKIN OINTMENT FOR TREATING LABIA MINORA SKIN
#186RECOMBINANT VIRAL VACCINES
#187NANOPARTICLES INCLUDING A GLATIRAMOID USEFUL IN POLYNUCLEOTIDE DELIVERY
#188Methods and Compositions for Antibody and Antibody-loaded Dendritic Cell Mediated Therapy
#189TP53 AS BIOMARKER FOR RESPONSIVENESS TO IMMUNOTHERAPY
#190PSMA ANTIBODY-DRUG CONJUGATES
#191GLUCOCORTICOID RECEPTOR AGONIST AND IMMUNOCONJUGATES THEREOF
#192SOLID DELIVERY COMPOSITION
#193Compositions for stabilizing and delivering proteins
#194ETANERCEPT FORMULATIONS STABILIZED WITH XYLITOL
#195Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
#196COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
#197Use of mRNAs encoding OX40L, IL-23 and IL-36gamma in combination with immune checkpoint blockade for treating particular cancers
#198XCR1 BINDING AGENTS AND USES THEREOF
#199MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS
#200Methods of CD40 and toll like receptor immune activation
#201USES OF PD-1/PD-L1 INHIBITORS AND/OR CTLA-4 INHIBITORS WITH A BIOLOGIC CONTAINING MULTIPLE CYTOKINE COMPONENTS TO TREAT CANCER
#202Methods for administering STING agonists
#203Compositions containing HC-HA/PTX3 complexes and methods of use thereof
#204Composition comprising a peptide and an inhibitor of viral neuraminidase
#205AUTOLOGOUS AND ALLOGENIC MACROPHAGES AND MONOCYTES FOR USE IN THERAPEUTIC METHODS
#206Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
#207Treatment of Diseases and Conditions Caused by Increased Vascular Permeability
#208MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES
#209NITRIC OXIDE- AND FAS LIGAND- ELUTING COMPOSITIONS AND DEVICES AND METHODS OF TREATMENT USING SAME
#210VECTORS CONDITIONALLY EXPRESSING THERAPEUTIC PROTEINS, HOST CELLS COMPRISING THE VECTORS, AND USES THEREOF
#211Compositions and methods of modulating macrophage activity
#212Method treating malignant ascites and metastatic pleural effusion with and disulfide-linked trimeric TRAIL
#213Method for treating cancer using disulfide-linked trimeric 4-1BBL
#214TARGETING GAMMA-DELTA T CELLS IN OBESITY AND CACHEXIA
#215Collagen-mimetic peptide mediated delivery of nucleic acid carriers for efficient delivery from collagen
#216METHODS OF TREATING NEUROLOGICAL DISEASES
#217NANOCOMPLEXES FOR REMOTELY-TRIGGERED GUEST MOLECULE RELEASE AND METHODS FOR FABRICATING THE SAME
#218Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
#219METHOD FOR TREATING ANTI-HER2 THERAPY-RESISTANT MUC4+ HER2+ CANCER
#220GITRL FUSION PROTEINS AND USES THEREOF
#221COMPOSITIONS AND METHODS RELATED TO ENGINEERED ERYTHROID CELLS COMPRISING IL-15
#222REGULATORY B CELLS AND USES THEREOF
#223HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use
#224Compositions and methods for in vitro activation and expansion of serial killer T cell populations and passive immunization of a cancer patient with tumor cell killing cells
#225TISSUE HEALING AGENT
#226IL2 and TNF mutant immunoconjugates
#227Methods of inducing responsiveness to anti-angiogenic agent
#228RADIOFREQUENCY FIELD HYPERTHERMIA AND SOLID TUMOR IMMUNOMODULATION
#229Modified polynucleotides for the production of secreted proteins
#230Methods related to engineered erythoid cells comprising 4-1BBL
#231ONCOLYTIC VACCINIA VIRUS CANCER THERAPY
#232ONCOLYTIC VIRUS THERAPY
#233TRAILshort antibody and methods of use
#234Preventive or therapeutic method for inflammatory skin disease
#235Compositions for biological systems and methods for preparing and using the same
#236Methods and compounds for the treatment or prevention of severe influenza
#237Compositions and methods for inhibiting the biological activity of soluble biomolecules
#238STEROID ADMINISTRATION AND IMMUNOTHERAPY
#239RNA for treatment or prophylaxis of a liver disease
#240Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
#241COMPOSITIONS AND METHODS TO INDUCE TARGETED APOPTOSIS BY MODULATING PROTEIN TYROSINE PHOSPHATASE 13 (PTPN13)
#242Polymeric nanoparticles providing nucleic acids encoding TNF-α
#243Packaging cell for making a pseudotyped lentivirus
#244Modified polynucleotides for the production of secreted proteins
#245In vivo production of proteins
#246Modified cell expansion and uses thereof
#247Composition Comprising a Peptide and an Inhibitor of Viral Neuraminidase
#248Engineered CD46-specific effector cells and uses thereof in the treatment of cancer
#249Method of reducing formation of etanercept aggregates or fragments
#250Therapeutic cell systems and methods for treating cancer and infectious diseases
#251Stable aqueous etanercept composition
#252Method of reducing formation of etanercept aggregates or fragments
#253Stable aqueous etanercept composition
#254Method of Reducing Formation of Etanercept Aggregates or Fragments
#255DR5 RECEPTOR AGONIST COMBINATIONS
#256Compositions and methods for promoting the mineralization of biological tissue
#257Nanopatterned medical device with enhanced cellular interaction
#258Methods of treating cancer
#259IL-15 variants and uses thereof
#260Stable pharmaceutical formulation
#261MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS
#262Etanercept formulations stabilized with amino acids
#263Detection of CD5 and methods and compositions for modulating CD5
#264PHARMACEUTICAL COMPOSITION FOR TREATMENT OF THE PULMONARY FORM OF ALTITUDE SICKNESS CAUSED BY LACK OF OXYGEN AND REDUCED AIR PRESSURE
#265Composite microneedle array including nanostructures thereon
#266Noxipoints stimulating devices using light, mechanical force, or heat as a source of stimulation
#267Etanercept formulations stabilized with xylitol
#268Multipotential Expanded Mesenchymal Precursor Cell Progeny (MEMP) and Uses Thereof
#269Compositions containing HC-HA/PTX3 complexes and methods of use thereof
#270Glucocorticoid receptor agonist and immunoconjugates thereof
#271COMPOSITIONS, SYSTEMS AND METHODS FOR GENE EXPRESSION NOISE DRUG SCREENING AND USES THEREOF
#272Transdermal delivery of high viscosity bioactive agents
#273AGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR 2 ANTIBODIES
#274Methods for generating macrophages with enhanced cancer phagocytosis
#275METABOLICALLY ACTIVATED RECOMBINANT VIRAL VECTORS AND METHODS FOR THEIR PREPARATION AND USE
#276Pulsed introduction of low-dose RANKL as a therapy for diet-induced atherosclerosis
#277Biomaterial comprising adipose-derived stem cells and method for producing the same
#278Compositions and methods related to multimodal therapeutic cancer indications
#279Therapeutic and Diagnostic Methods for Autoimmune Diseases and/or Inflammation
#280Mesenchymal Stem Cells Expressing Biomarkers that Predict the Effectiveness of Mesenchymal Stem Cells for Treating Diseases and Disorders
#281Methods of producing activated mesenchymal stem cells
#282Method for preventing and treating hyperpermeability
#283Compositions and methods for inhibiting the biological activity of soluble biomolecules
#284MESENCHYMAL STEM CELL EXPRESSING TRAIL AND CD, AND USE THEREOF
#285ANTI-NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE ANTIBODY GENES AND METHODS OF USE THEREOF
#286System and method for treating inflammation
#287Methods for inducing migration by dendritic cells and an immune response
#288TRIMERIC COSTIMULATORY TNF FAMILY LIGAND-CONTAINING ANTIGEN BINDING MOLECULES
#289Nucleic acids encoding HLA-A24 agonist epitopes of MUC1-C oncoprotein
#290Ameliorating systemic sclerosis with death receptor agonists
#291THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF DRY EYE AND RELATED OCULAR SURFACE DISEASES
#292Compositions and methods for treating opioid tolerance
#293MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF COSMETIC PROTEINS AND PEPTIDES
#294ATTENUATION OF INTRAPULMONARY INFLAMMATION
#295METHOD AND MEDICAMENT FOR TREATING AIRWAY AND/OR LUNG DISEASES
#296KEXIN-DERIVED VACCINES TO PREVENT OR TREAT FUNGAL INFECTIONS
#297Modified Polynucleotides for the production of biologics and proteins associated with human disease
#298Use of immunomodulatory kits for immunotherapeutic treatment of patients with myeloid leukemias
#299Early cancer detection and enhanced immunotherapy
#300Treatment of diseases and conditions caused by increased vascular permeability